AUTHORS
Thura Win Htut, MD, FRCPath, Wei Ying Jen, BM BCh, FRCPath2, Leticia Campoverde, MD3, Alexandre Bazinet, MD, MSc4, Uday Popat, MD, MBA5, Ian Bouligny, M.D.6, Naval Daver, MD7, Guillermo Garcia-Manero, MD8, Nicholas Short, MD9, Ghayas C. Issa, MD10, Abhishek Maiti, MBBS11, Jayastu Senapati, MBBS, MD, DM12, Musa Yilmaz, MD13, Betul Oran, MD14, Amin Alousi, MD15, Rohtesh Mehta, MD, MPH16, Samer A Srour, MB ChB, MS17, Jin Im, MD, PhD18, Elizabeth Shpall, MD19, Farhad Ravandi, MD20, Hagop Kantarjian, MD21, Courtney DiNardo, MD, MSCE22, Tapan Kadia I, MD23
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Although allogenic stem cell transplantation (SCT) remains the most effective consolidation strategy for many patients (pts) with newly diagnosed acute myeloid leukemia (ND AML), the impact of adding venetoclax (VEN) to frontline intensive chemotherapy (IC) on post-SCT outcomes remain uncertain. We evaluated the impact of IC+VEN on pre-SCT measurable residual disease (MRD), relapse, and post-SCT survival compared with IC alone.
Methods
We retrospectively analyzed pts with AML undergoing first SCT in first remission after frontline IC or IC+Ven at our institution between April 2010 and July 2026. IC regimens were clofarabine, idarubicin, cytarabine (CIA), cladribine, cytarabine, idarubicin (CLIA), fludarabine, cytarabine, GCSF, and idarubicin (FLAG-IDA), fludarabine, cytarabine, idarubicin (FAI), and idarubicin with high-dose cytarabine (IA/HDAC). VEN-based regimens were CLIA+VEN and FLAG-IDA+VEN. All regimens included cytarabine doses of 1 g/m2 or higher during induction. To isolate the impact of VEN and chemotherapy pts receiving concurrent FLT3 inhibitor therapy during induction were excluded from the study. Endpoints were complete remission (CR)/CR with incomplete hematologic recovery (CRi), pre-SCT MRD status, overall survival (OS) and event-free survival (EFS) from SCT, cumulative incidence of relapse (CIR), non-relapse mortality (NRM). Kaplan Meier, competing risk, and COX proportional hazards analyses were performed.
Results
All 236 pts underwent SCT in first CR (CR1), including 136 treated with IC+VEN and 100 treated with IC. Median age was 48 years (y) (range, 18-67). Pts received a median of 2 (range, 1-5) cycles of IC prior to SCT in both groups. Baseline ELN 2022 risk distribution was similar in 2 groups (adverse risk, 45% in IC+VEN vs 47% in IC). Complex karyotype was more frequent in the IC than IC+VEN groups (24% vs 10%). The rates of CR/CRi prior to SCT were high in both groups, although IC+VEN produced deeper remissions. The rates of CR/CRi were 86%/11% and 94%/5% for pts receiving IC+VEN and IC, respectively. IC+VEN was associated with a higher rate of pre-SCT MRD negativity among all evaluable pts (91% vs 80%; P=0.02).
Post-SCT outcomes differed according to prior evaluable MRD status. At a median follow up of 35.9 months (m) in IC+VEN and 130.5 m in IC groups, pts achieving MRD negativity before SCT had superior OS (median NR vs 14.3 m, P<0.001) and EFS (median NR vs 7.9 m, P<0.001) compared with MRD-positive pts. Among pts who were MRD-negative by flow cytometry prior to SCT, IC+VEN resulted in superior post-SCT outcomes compared with IC (median OS NR in both groups, 2-yr OS 87.1% vs. 74.4%; P=0.018), whereas no difference was observed among MRD-positive pts (median 18.9 vs 13.7 m, P=0.75) receiving IC+VEN and IC.
IC+VEN significantly reduced post-SCT relapse. The cumulative incidence of relapse at 12 and 24 m was 7.3% and 8.3% following IC+VEN compared with 21.2% each following IC (Gray’s P=0.009). Corresponding 24-month NRM was 8.7% vs 16.2% in IC+VEN and IC. Estimated 2-and 5-y OS rates were 83.3%, 77.6% in the IC+VEN compared with 65.7%, 57.2% in the IC groups.
In the overall cohort, maintenance therapy post SCT was not independently associated with OS (HR 0.79, 95% CI 0.44-1.41; P=0.40). On univariate analysis, IC+VEN was associated with improved OS compared with IC alone (HR 0.5, 95% CI 0.30-0.85; P=0.009). MRD positivity (HR 3.46, P<0.001), complex karyotype (HR 2.51, P=0.001), -5/del5q (HR 4.55, P<0.001), -7/del7q (HR 2.82, P=0.004), and -17p/del17p (HR 3.75, P=0.018) were associated with inferior OS, whereas ASXL1 (HR 0.17, P=0.016) and NRAS mutations (HR 0.33, P=0.013) was associated with improved OS. In multivariate total-effect model adjusted for baseline characteristics, IC+VEN was associated with numerically lower risk of death (HR 0.61, 95% CI 0.35-1.05; P=0.07), while -7/del7q independently predicted inferior OS (HR 1.91, 95%CI, 1.04-3.64; P=0.04).
Conclusion
Frontline IC+VEN was associated with deeper remissions, significantly higher pre-SCT MRD negativity, and lower post-SCT relapses compared with IC alone. While pre-SCT MRD remained a major determinant of post-SCT survival, IC+VEN was associated with superior outcomes even among pts who were MRD negative prior to SCT. These findings support incorporating intensive VEN based induction as a promising approach for SCT-eligible pts with AML and provide a rationale for prospective studies evaluating MRD-guided SCT strategies.
DISCLOSURES
Thura Win Htut, MD, FRCPath: No relevant conflicts of interest to declare.